早期中枢神经系统症状与重型2019冠状病毒病的关联:多中心观察性病例系列研究
该回顾性观察性病例系列研究基于美国佛罗里达州五个医疗系统的电子健康记录,纳入36,615例确诊COVID-19患者,其中4,417例(12%)发展为重型COVID-19。研究评估诊断前14天至诊断后8天内(或重型诊断前,以先发生者为准)的早期中枢神经系统症状与重型COVID-19的关联。重型患者出现早期中枢神经系统症状的比例为32.8%,显著高于非重型患者的6.11%(χ2[1]=3,266.08,p<0.0001,φ=0.29)。调整人口学变量和相关合并症后,早期中枢神经系统症状与重型COVID-19显著相关(OR=3.21);脑病与重型风险增加相关(OR=14.38),而嗅觉丧失(OR=0.45)、味觉丧失(OR=0.46)和头痛(OR=0.63)与重型风险降低相关。
要点
- 重型COVID-19患者早期中枢神经系统症状发生率为32.8%,显著高于非重型患者的6.11%(χ2[1]=3,266.08,p<0.0001,φ=0.29)。
- 调整人口学变量和相关合并症后,早期中枢神经系统症状与重型COVID-19显著相关(OR=3.21)。
- 脑病与重型COVID-19风险增加相关(OR=14.38)。
- 嗅觉丧失(OR=0.45)、味觉丧失(OR=0.46)和头痛(OR=0.63)与重型COVID-19风险降低相关。
- 早期中枢神经系统症状可能作为临床病程差异的早期标志物。
适用人群与场景
- 美国佛罗里达州五个医疗系统内确诊COVID-19的患者(n=36,615)。
- 重型COVID-19定义为需要重症监护、机械通气,或诊断为急性呼吸窘迫综合征、脓毒症或严重炎症反应综合征。
诊断标准与关键阈值
- 早期中枢神经系统症状定义为在COVID-19诊断前14天至诊断后8天内,或重型COVID-19诊断日期之前(以先发生者为准)诊断的脑病、头痛、味觉丧失、嗅觉丧失、头晕或急性脑血管病。
研究设计与关键结果
- 研究设计为回顾性观察性病例系列,纳入美国佛罗里达州五个医疗系统的36,615例确诊COVID-19患者,其中4,417例(12%)发展为重型COVID-19。
- 重型COVID-19患者出现早期中枢神经系统症状的比例为32.8%,非重型患者为6.11%(χ2[1]=3,266.08,p<0.0001,φ=0.29)。
- 调整人口学变量和相关合并症后,早期中枢神经系统症状与重型COVID-19显著相关(OR=3.21)。
- 脑病与重型COVID-19风险增加相关(OR=14.38)。
- 嗅觉丧失(OR=0.45)、味觉丧失(OR=0.46)和头痛(OR=0.63)与重型COVID-19风险降低相关。
证据类型、等级与局限
- 证据类型:回顾性观察性病例系列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,早期中枢神经系统症状,特别是脑病,是重型COVID-19风险不同的关联因素,可能作为临床病程差异的早期标志物。
- 作者认为,COVID-19早期治疗手段匮乏,进一步识别高危亚组可能有助于加深对严重程度轨迹的理解并实现针对性治疗。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
UNLABELLED: To determine if early CNS symptoms are associated with severe coronavirus disease 2019.
DESIGN: A retrospective, observational case series study design.
SETTING: Electronic health records were reviewed for patients from five healthcare systems across the state of Florida, United States.
PATIENTS: A clinical sample (n = 36,615) of patients with confirmed diagnosis of coronavirus disease 2019 were included. Twelve percent (n = 4,417) of the sample developed severe coronavirus disease 2019, defined as requiring critical care, mechanical ventilation, or diagnosis of acute respiratory distress syndrome, sepsis, or severe inflammatory response syndrome.
INTERVENTIONS: None.
MEASUREMENT AND MAIN RESULTS: We reviewed the electronic health record for diagnosis of early CNS symptoms (encephalopathy, headache, ageusia, anosmia, dizziness, acute cerebrovascular disease) between 14 days before the diagnosis of coronavirus disease 2019 and 8 days after the diagnosis of coronavirus disease 2019, or before the date of severe coronavirus disease 2019 diagnosis, whichever came first. Hierarchal logistic regression models were used to examine the odds of developing severe coronavirus disease 2019 based on diagnosis of early CNS symptoms. Severe coronavirus disease 2019 patients were significantly more likely to have early CNS symptoms (32.8%) compared with nonsevere patients (6.11%; χ2[1] = 3,266.08, p < 0.0001, φ = 0.29). After adjusting for demographic variables and pertinent comorbidities, early CNS symptoms were significantly associated with severe coronavirus disease 2019 (odds ratio = 3.21). Diagnosis of encephalopathy (odds ratio = 14.38) was associated with greater odds of severe coronavirus disease 2019; whereas diagnosis of anosmia (odds ratio = 0.45), ageusia (odds ratio = 0.46), and headache (odds ratio = 0.63) were associated with reduced odds of severe coronavirus disease 2019.
CONCLUSIONS: Early CNS symptoms, and specifically encephalopathy, are differentially associated with risk of severe coronavirus disease 2019 and may serve as an early marker for differences in clinical disease course. Therapies for early coronavirus disease 2019 are scarce, and further identification of subgroups at risk may help to advance understanding of the severity trajectories and enable focused treatment.
参考来源
- Marra DE, Busl KM, Robinson CP, et al. Examination of Early CNS Symptoms and Severe Coronavirus Disease 2019: A Multicenter Observational Case Series. Crit Care Explor. 2021. PMID: 34136827. doi:10.1097/CCE.0000000000000456
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。